Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...

HC Wainwright dropped their FY2025 earnings estimates for shares of LightPath Technologies in a report released on Tuesday, February 18th. HC Wainwright analyst S. Buck now expects that the technology ...

H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

Looking at options history for Cleanspark CLSK we detected 29 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...

On Tuesday, H.C. Wainwright reaffirmed a positive outlook on OKYO Pharma Ltd. (NASDAQ: OKYO), maintaining a Buy rating and a $7.00 price target. Currently trading at $1.10, with a market ...

will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. An audio webcast of the event will be available on the Company's ...

On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $12.00 price target for Grace Therapeutics (NASDAQ:GRCE), which currently trades at $3.45 with a market cap of $35 million. According to ...

On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $12.00 price target for Grace Therapeutics (NASDAQ:GRCE), which currently trades at $3.45 with a market cap of $35 million. According to ...